Medically reviewed by Jay N. Yepuri, MD PBC is a chronic liver disease that damages bile ducts and can lead to liver failure. You can get treatment for PBC to slow disease progression and manage ...

(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...

GSK’s linerixibat has shown promising results in a late-stage trial of primary biliary cholangitis (PBC) patients with cholestatic pruritus, or relentless itch. The phase 3 GLISTEN trial has been ...

Approval of Livdelzi is based on results from the Phase III RESPONSE study, which demonstrated improved key biochemical markers and reduced pruritus. The FDA has granted accelerated approval to ...

(MENAFN- GlobeNewsWire - Nasdaq) The dynamics of the primary biliary cholangitis market are anticipated to change during the forecast period owing to the rising prevalence of PBC, robust pipeline with ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

This indication was approved under accelerated approval based on a reduction of alkaline phosphatase. The Food and Drug Administration (FDA) has granted accelerated approval to Iqirvo ® (elafibranor) ...

The appraisal committee has prepared final draft guidance (FDG) on elafibranor for treating primary biliary cholangitis and submitted it to NICE. The FDG has been sent to consultees for this appraisal ...

- Designation based on positive interim analysis of Phase 2b VANTAGE study "Breakthrough Therapy Designation for volixibat in PBC underscores the importance and urgency for a treatment to address one ...

There is a simple discount patient access scheme for elafibranor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...